TY - JOUR
T1 - Endurance exercise reduces hepatic fat content and serum fibroblast growth factor 21 levels in elderly men
AU - Taniguchi, Hirokazu
AU - Tanisawa, Kumpei
AU - Sun, Xiaomin
AU - Kubo, Takafumi
AU - Higuchi, Mitsuru
N1 - Publisher Copyright:
Copyright © 2016 by the Endocrine Society.
PY - 2016/1
Y1 - 2016/1
N2 - Context: Age-related hepatic fat accumulation increases the risk of cardiometabolic diseases, and the fibroblast growth factor (FGF) 21â€"resistant state caused by fatty liver underlies the pathogenesis of these diseases. Objective: Previous studies suggested that a higher level of cardiorespiratory fitness was associated with both lower hepatic fat contentandserum FGF21 levels; however, the effect of endurance exercise on hepatic fat content and serum FGF21 concentration has not been studied. Therefore, we aimed to elucidate whether endurance exercise reduced hepatic fat content and serum FGF21 levels. Design: This is a randomized crossover trial. Setting: The study setting was an institutional practice. Patients: Thirty-three elderly Japanese men participated in the study. Intervention: The intervention was a 5-week endurance exercise program comprising three cycle ergometer sessions per week. Main Outcome Measures: Hepatic fat content was assessed by proton magnetic resonance spectroscopy, and serum FGF21 level was determined by ELISA. Results:A5-week endurance exercise program decreased the hepatic fat content and serum FGF21 levels without weight loss, and the changes were higher in the exercise period than in the control period (P=.021andP=.026, respectively). Correlation analysis demonstrated that only the change in hepatic fat content was significantly and positively correlated with change in serum FGF21 levels (r = 0.366, P = .006). Conclusions: A 5-week endurance exercise program decreased hepatic fat content and serum FGF21 levels without weight loss in elderly men, and exercise-induced hepatic fat reduction mediated the reduction in serum FGF21 levels. These findings suggest that endurance exercise modulates hepatic fat content and FGF21 resistance, regardless of obesity status.
AB - Context: Age-related hepatic fat accumulation increases the risk of cardiometabolic diseases, and the fibroblast growth factor (FGF) 21â€"resistant state caused by fatty liver underlies the pathogenesis of these diseases. Objective: Previous studies suggested that a higher level of cardiorespiratory fitness was associated with both lower hepatic fat contentandserum FGF21 levels; however, the effect of endurance exercise on hepatic fat content and serum FGF21 concentration has not been studied. Therefore, we aimed to elucidate whether endurance exercise reduced hepatic fat content and serum FGF21 levels. Design: This is a randomized crossover trial. Setting: The study setting was an institutional practice. Patients: Thirty-three elderly Japanese men participated in the study. Intervention: The intervention was a 5-week endurance exercise program comprising three cycle ergometer sessions per week. Main Outcome Measures: Hepatic fat content was assessed by proton magnetic resonance spectroscopy, and serum FGF21 level was determined by ELISA. Results:A5-week endurance exercise program decreased the hepatic fat content and serum FGF21 levels without weight loss, and the changes were higher in the exercise period than in the control period (P=.021andP=.026, respectively). Correlation analysis demonstrated that only the change in hepatic fat content was significantly and positively correlated with change in serum FGF21 levels (r = 0.366, P = .006). Conclusions: A 5-week endurance exercise program decreased hepatic fat content and serum FGF21 levels without weight loss in elderly men, and exercise-induced hepatic fat reduction mediated the reduction in serum FGF21 levels. These findings suggest that endurance exercise modulates hepatic fat content and FGF21 resistance, regardless of obesity status.
UR - http://www.scopus.com/inward/record.url?scp=84954528539&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84954528539&partnerID=8YFLogxK
U2 - 10.1210/jc.2015-3308
DO - 10.1210/jc.2015-3308
M3 - Article
C2 - 26562755
AN - SCOPUS:84954528539
SN - 0021-972X
VL - 101
SP - 191
EP - 198
JO - Journal of Clinical Endocrinology and Metabolism
JF - Journal of Clinical Endocrinology and Metabolism
IS - 1
ER -